Denosumab 60 MG/ML

DRUG4 trials

Sponsors

Australian and New Zealand Intensive Care Research Centre, Nigde Omer Halisdemir University, Western University, Canada, Susan L. Greenspan

Conditions

Chronic Kidney Disease-Mineral and Bone DisorderCritical IllnessDialysis; ComplicationsFragility FractureKidney DiseasesOsteoporosisPostmenopausal Osteoporosis

Phase 2

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

RecruitingNCT04608630

Australian and New Zealand Intensive Care Research CentreCritical Illness, Osteoporosis

Start: 2021-07-15End: 2027-02-28Target: 450Updated: 2026-03-04

Phase 4

PRevEnting FracturEs in REnal Disease - 1

Active, not recruitingNCT05096195

Western University, CanadaChronic Kidney Disease-Mineral and Bone Disorder, Dialysis; Complications, Fragility Fracture +1

Start: 2022-06-11End: 2025-12-31Target: 60Updated: 2025-05-31

Preserving Geriatric Muscle With an Osteoporosis Medication

RecruitingNCT06118905

Susan L. GreenspanOsteoporosis

Start: 2024-02-08End: 2029-03-31Target: 155Updated: 2026-02-10

Unknown Phase

Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients

CompletedNCT04702204

Nigde Omer Halisdemir UniversityPostmenopausal Osteoporosis

Start: 2020-07-01End: 2021-08-15Updated: 2021-09-01

Related Papers

PRevEnting FracturEs in REnal Disease-1 (PREFERRED-1): protocol for a pilot study of a pragmatic, randomised controlled trial of denosumab for the prevention of fragility fractures in haemodialysis

BMJ Open2025-09-01